Parenting, Perinatal Substance Use, Substance Use Treatment
Conditions
Brief summary
Drug overdose is a leading cause of death among postpartum women and opioid-related mortality is 4 times higher in the postpartum period when compared to the third trimester of pregnancy. Medications for opioid use disorder (MOUD; e.g., methadone or buprenorphine) are the recommended standard of care for perinatal women with OUD. Studies indicate that 50-60% of perinatal women with OUD initiate medications during pregnancy; however, over half will prematurely discontinue treatment within the first six months of childbirth due to stressors experienced in the postpartum period. Common stressors that contribute to MOUD treatment discontinuation in this population are return to opioid use, mental health symptoms including depression, parenting-related stressors such as challenges in infant care and bonding, Neonatal Abstinence Syndrome (NAS), child welfare involvement, and feelings of guilt, shame, and stigma. Thus, there is an urgent need to develop effective, recovery-oriented support interventions that promote the initiation and continuity of MOUD treatment in the postpartum period. The current study utilizes community-engaged research methods to identify and prioritize the early parenting-related needs of postpartum women receiving MOUD to inform the adaptation and implementation of an evidence-based parenting intervention for this population receiving outpatient treatment for opioid use disorder.
Interventions
BEHAVIORALProud of Baby and Me
The original Baby \& Me curricula was adapted to be delivered in outpatient substance use treatment settings to newly postpartum women receiving medications for opioid use disorder (MOUD) for this study.
Sponsors
University of Arkansas
National Center for Advancing Translational Sciences (NCATS)
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* 18 years or older * Understand and speak English * Able to give informed consent * Receiving medications for opioid use disorder in the outpatient clinical setting * Between 28 weeks gestation and up to 12 months postpartum
Exclusion criteria
* Unwilling to consent * Before 28 weeks gestation and beyond 12 months postpartum at enrollment
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Program Utilization | Up to 12 months after delivery | % of eligible women who choose to enroll in Baby \& Me |
| Program Acceptability | Up to 12 months after delivery | Self-report ratings of the acceptability of Proud of Baby \& Me |
| Client Satisfaction | Up to 12 months after delivery | Self-reported scores on the Client Satisfaction Questionnaire |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Depressive Symptoms | Up to 12 months after delivery | Self-report scores of the Edinburg Postnatal Depression Scale |
| Parental Stress | Up to 12 months after delivery | Self-reported scores on the Parenting Stress Index - Short Form |
| Parenting Confidence | Up to 12 months after delivery | Self-reported scores of perceived parenting confidence on the Karitane Parenting Confidence Scale |
Countries
United States
Contacts
CONTACTMollee K Steely Smith, PhD
PRINCIPAL_INVESTIGATORMollee K Steely Smith, PhD
University of Arkansas
Outcome results
None listed